			-		
Doc.:	INS HTLVABULTRA.CE/eng	Page	1 of 8	Rev.: 4	Date: 2021/05

# HTLV I&II Ab Version ULTRA

Enzyme Immunoassay for the determination of antibodies to Human T-Cell Lymphotropic Virus type I&II in serum and plasma

- for "in vitro" diagnostic use only -



DIA.PRO Diagnostic Bioprobes Srl Via G. Carducci n° 27 20099 Sesto San Giovanni (MI) - Italy Phone +39 02 27007161

Fax +39 02 44386771 e-mail: <u>info@diapro.it</u>

> REF HTLVABULTRA.CE 96/192/480/960 Tests

## HTLV I&II Ab ULTRA

#### A. INTENDED USE

Enzyme ImmunoAssay (ELISA) for the qualitative determination of antibodies to Human T-cell Lymphotropic Virus type I&II or HTLV I&II Ab. The kit is intended for the screening of blood units and the follow-up of HTLV I&II-infected patients. For "in vitro" diagnostic use only.

#### **B. INTRODUCTION**

HTLV I&II are retroviruses not related genetically to HIV1&2; however, they have similar routes of transmission and can have extremely long period of latency prior to manifestation of disease.

HTLV I is endemic in southern Japan, the Caribbean and the US and many other scattered population trough the world.

HTLV II is endemic in some native American populations but is detected mostly in intravenous drug users and their sexual partners.

HTLV I&II are transmitted transplacentally, parenterally, by sexual contacts and by infected blood.

ELISA has been applied to the diagnosis of HTLV I&II serology by detecting specific antibodies in plasma and sera.

## C. PRINCIPLE OF THE TEST

Microplates are coated with HTLV I&II specific synthetic immunodominant antigens derived from gp46-I, gp46-II and gp21.

The solid phase is first treated with the sample and anti HTLV I&II Ab are captured, if present, by the antigens coated on the microplate.

After washing out all the other components of the sample, in the second incubation bound anti HTLV I&II total antibodies, are detected by the addition of specific synthetic antigens derived from gp46-I, gp46-II and gp21, labelled with peroxidase (HRP).

The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti HTLV I&II antibodies present in the sample. After blocking the enzymatic reaction, its optical density is measured by an ELISA reader.

The version ULTRA is particularly suitable for automated screenings.

#### **D. COMPONENTS**

The standard configuration of the kit contains sufficient reagents to perform 192 tests.

#### 1. Microplate: MICROPLATE

n° 2 microplates. 12 strips of 8 breakable wells. Microplates are coated with HTLV I&II specific synthetic immunodominant antigens derived from gp46-I, gp46-II and gp21. Plates are sealed into a bag with desiccant. Allow the microplate to reach room temperature before opening; reseal unused strips in the bag with desiccant and store at +4°C.

#### 2. Negative Control CONTROL -

1x4.0ml/vial. Ready to use control. It contains 5% BSA, 10mM phosphate buffer pH 7.4 ±0.1, 0.09% sodium azide 0.045% ProClin 300. Brown/yellow colour coded.

#### 3. Positive Control CONTROL +

1x4.0ml/vial. Ready to use control. It contains 5% BSA, 10mM phosphate buffer pH 7.4  $\pm$ 0.1, 0.09% sodium azide, inactivated human serum positive to HTLV Ab, 0.045% ProClin 300.. Green colour coded.

#### 4. Calibrator: CAL ...ml

N° 2 vials. Lyophilized calibrator. It contains inactivated anti HTLV I&II antibodies, calibrated agains Seracare Accurun 24, 4% BSA, 2% Mannitol, 50mM Tris buffer pH 7.8, 0.2 mg/ml gentamicine sulphate and 0.045% ProClin 300.

Note: The volume necessary to dissolve the content of the vial may vary from lot to lot. Please use the right volume reported on the label.

#### 5. Wash buffer concentrate WASHBUF 20X

2x60ml/bottle. 20x concentrated solution containing 0.045% ProClin 300. as preservative. Once diluted, the wash solution contains 10 mM phosphate buffer pH 7.0  $\pm0.2$  and 0.05% Tween 20.

#### 6. Enzyme conjugate : CONJ

1x25.0 ml/bottle. Ready-to-use solution. It contains HTLV synthetic antigens mixture, labelled with HRP, 5% BSA, 10 mM Tris buffer pH 6.8  $\pm$ 0.1, 0.3 mg/ml gentamicine sulphate and 0.045% ProClin 300. as preservatives. Pink/red color coded.

#### 7. Chromogen/Substrate SUBS TMB

1x25ml/bottle. Ready-to-use component. It contains 50 mM citrate-phosphate buffer pH 3.5-3.8, 4% dimethylsulphoxide, 0.03% tetra-methyl-benzidine or TMB and 0.02% hydrogen peroxide or  $H_2O_2$ .

# Note: To be stored protected from light as sensitive to strong illumination.

#### 8. Sulphuric Acid: H2SO4 0.3 M

1x25ml/ bottle.Contains 0.3 M H<sub>2</sub>SO<sub>4</sub> solution. Attention: Irritant (H315; H319; P280; P302+P352; P332+P313; P305+P351+P338; P337+P313; P362+P363).

9. Plate sealing foil n° 4

#### 10. Package insert n° 1

**Important note:** Only upon specific request, Dia.Pro can supply reagents for 96, 480, 960 tests, as reported below :

Number of tests	96	480	960
Code	HTLVABULTRA.CE.96	HTLVABULTRA.CE.480	HTLVABULTRA.CE.960
1.Microplate	n°1	n°5	n°10
2.NegativeControl	1x2.0ml/vial	1x10ml/vial	1x20ml/vial
3.PositiveControl	1x2.0ml/vial	1x10ml/vial	1x20ml/vial
4.Calibrator	n° 1 vial	n° 5 vials	n° 10 vials
5.Wash buff conc	1x60ml/bottle	5x60ml/bottles	4x150ml/bottles
6.Enz. Conjugate	1x16ml/vial	2x40ml/bottles	4x40ml/bottles
7.Chromog/Subs	1x16ml/vial	2x40ml/bottles	4x40ml/bottles
8.Sulphuric Acid	1x15ml/vial	2x40ml/bottles	2x80ml/bottles
9.Plate seal foils	n° 2	n° 10	n° 20
10.Pack. insert	n° 1	n° 1	n° 1

#### E. MATERIALS REQUIRED BUT NOT PROVIDED

- 1. Calibrated Micropipettes (200µl and 10µl) and disposable plastic tips.
- 2. EIA grade water (bidistilled or deionised, charcoal treated to remove oxidizing chemicals used as disinfectants).
- 3. Timer with 60 minute range or higher.
- 4. Absorbent paper tissues.
- Calibrated ELISA microplate thermostatic incubator capable to provide a temperature of +37°C.
- 6. Calibrated ELISA microwell reader with 450nm (reading) and with 620-630nm (blanking) filters.
- 7. Calibrated ELISA microplate washer.
- 8. Vortex or similar mixing tools.

Doc.:	INS HTLVABULTRA.CE/eng	Page	3 of 8	Rev.: 4	Date: 2021/05	
-------	------------------------	------	--------	---------	---------------	--

#### F. WARNINGS AND PRECAUTIONS

1. The kit has to be used by skilled and properly trained technical personnel only, under the supervision of a medical doctor responsible of the laboratory.

2. When the kit is used for the screening of blood units and blood components, it has to be used in a laboratory certified and qualified by the national authority in that field (Ministry of Health or similar entity) to carry out this type of analysis.

3. All the personnel involved in performing the assay have to wear protective laboratory clothes, talc-free gloves and glasses. The use of any sharp (needles) or cutting (blades) devices should be avoided. All the personnel involved should be trained in biosafety procedures, as recommended by the Center for Disease Control, Atlanta, U.S. and reported in the National Institute of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.

4. All the personnel involved in sample handling should be vaccinated for HBV and HAV, for which vaccines are available, safe and effective.

5. The laboratory environment should be controlled so as to avoid contaminants such as dust or air-born microbial agents, when opening kit vials and microplates and when performing the test. Protect the Chromogen/Substrate from strong light and avoid vibration of the bench surface where the test is undertaken.

6. Upon receipt, store the kit at 2..8°C into a temperature controlled refrigerator or cold room.

7. Do not interchange components between different lots of the kits. It is recommended that components between two kits of the same lot should not be interchanged.

8. Check that the reagents are clear and do not contain visible heavy particles or aggregates. If not, advise the laboratory supervisor to initiate the necessary procedures for kit replacement.

9. Avoid cross-contamination between serum/plasma samples by using disposable tips and changing them after each sample. Do not reuse disposable tips.

10. Avoid cross-contamination between kit reagents by using disposable tips and changing them between the use of each one. Do not reuse disposable tips.

11. Do not use the kit after the expiration date stated on the external container and internal (vials) labels.

12. Treat all specimens as potentially infective. All human serum specimens should be handled at Biosafety Level 2, as recommended by the Center for Disease Control, Atlanta, U.S. in compliance with what reported in the Institutes of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.

13. The use of disposable plastic-ware is recommended in the preparation of the liquid components or in transferring components into automated workstations, in order to avoid cross contamination.

14. Waste produced during the use of the kit has to be discarded in compliance with national directives and laws concerning laboratory waste of chemical and biological substances. In particular, liquid waste generated from the washing procedure, from residuals of controls and from samples has to be treated as potentially infective material and inactivated before waste. Suggested procedures of inactivation are treatment with a 10% final concentration of household bleach for 16-18 hrs or heat inactivation by autoclave at +121°C for 20 min.

15. Accidental spills from samples and operations have to be adsorbed with paper tissues soaked with household bleach and then with water. Tissues should then be discarded in proper containers designated for laboratory/hospital waste.

16. The Sulphuric Acid is an irritant. In case of spills, wash the surface with plenty of water. Other waste materials generated from the use of the kit (example: tips used for samples and controls, used microplates) should be handled as potentially infective and disposed according to national directives and laws concerning laboratory wastes.

#### G. SPECIMEN: PREPARATION AND WARNINGS

- Blood is drawn aseptically by venipuncture and plasma or serum is prepared using standard techniques of preparation of samples for clinical laboratory analysis. No influence has been observed in the preparation of the sample with citrate, EDTA and heparin.
- Avoid any addition of preservatives to samples; especially sodium azide as this chemical would affect the enzymatic activity of the conjugate, generating false negative results.
- 3. Samples have to be clearly identified with codes or names in order to avoid misinterpretation of results. When the kit is used for the screening of blood units, bar code labeling and electronic reading is strongly recommended.
- 4. Haemolysed (red) and visibly hyperlipemic ("milky") samples have to be discarded as they could generate false results. Samples containing residues of fibrin or heavy particles or microbial filaments and bodies should be discarded as they could give rise to false results.
- 5. Sera and plasma can be stored at +2°..8°C primary collection tubes for up to seven days after collection. Do not freeze primary tubes of collection. For longer storage periods, sera and plasma samples, carefully removed from the primary collection tube, can be stored frozen at -20°C for at least 12 months. For longer storage periods, samples can be stored frozen at -20°C for several months. Any frozen samples should not be frozen/thawed more than once as this may generate particles that could affect the test result.
- If particles are present, centrifuge at 2.000 rpm for 20 min or filter using 0.2-0.8u filters to clean up the sample for testing.

#### H. PREPARATION OF COMPONENTS AND WARNINGS Microplate:

Allow the microplate to reach room temperature (about 1 hr) before opening the container. Check that the desiccant has not turned green, indicating a defect in conservation. In this case, call Dia.Pro's customer service.

Unused strips have to be placed back into the aluminum pouch, with the desiccant supplied, firmly zipped and stored at +2°-8°C. After first opening, remaining strips are stable until the humidity indicator inside the desiccant bag turns from yellow to green.

#### **Negative and Positive Controls:**

Ready to use. Mix well on vortex before use.

#### Calibrator:

Add the volume of ELISA grade water, reported on the label, to the lyophilised powder; let fully dissolve and then gently mix on vortex.

**Note:** The calibrator after dissolution is not stable. Store frozen in aliquots at -20 °C.

#### Wash buffer concentrate:

The whole content of the concentrated solution has to be diluted 20x with bidistilled water and mixed gently end-over-end before use. During preparation avoid foaming as the presence of bubbles could impact on the efficiency of the washing cycles. *Note: Once diluted, the wash solution is stable for 1 week at* +2..8° C.

#### Enzyme conjugate:

Ready to use. Mix well on vortex before use.

Avoid contamination of the liquid with oxidizing chemicals, dust or microbes. If this component has to be transferred, use only plastic, and if possible, sterile disposable containers.

#### Chromogen/Substrate:

Ready to use. Mix well on vortex before use. Avoid contamination of the liquid with oxidizing chemicals, air-

driven dust or microbes. Do not expose to strong light, oxidizing agents and metallic surfaces.

Doc.: INS HTLVABULTRA.CE/eng	Page	4 of 8	Rev.: 4	Date: 2021/05
------------------------------	------	--------	---------	---------------

If this component has to be transferred use only plastic, and if possible, sterile disposable container.

#### Sulphuric Acid:

Ready to use. Mix well on vortex before use. Attention: Irritant (H315; H319; P280; P302+P352; P332+P313; P305+P351+P338; P337+P313; P362+P363).

Legenda:

Warning **H statements:** H315 – Causes skin irritation. H319 – Causes serious eye irritation.

Precautionary P statements:

P280 - Wear protective gloves/protective clothing/eye protection/face protection.

P302 + P352 – IF ON SKIN: Wash with plenty of soap and water.

P332 + P313 – If skin irritation occurs: Get medical advice/attention. P305 + P351 + P338 – IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313 – If eye irritation persists: Get medical advice/attention.

P337 + P313 – If eye irritation persists: Get medical advice/attention.
 P362 + P363 - Take off contaminated clothing and wash it before reuse.

# I. INSTRUMENTS AND TOOLS USED IN COMBINATION WITH THE KIT

- Micropipettes have to be calibrated to deliver the correct volume required by the assay and must be submitted to regular decontamination (household alcohol, 10% solution of bleach, hospital grade disinfectants) of those parts that could accidentally come in contact with the sample. They should also be regularly maintained in order to show a precision of 1% and a trueness of ±2%. Decontamination of spills or residues of kit components should also be carried out regularly.
- The ELISA incubator has to be set at +37°C (tolerance of ±0.5°C) and regularly checked to ensure the correct temperature is maintained. Both dry incubators and water baths are suitable for the incubations, provided that the instrument is validated for the incubation of ELISA tests.
- 3. The ELISA washer is extremely important to the overall performances of the assay. The washer must be carefully validated in advance, checked for the delivery of the right dispensation volume and regularly submitted to maintenance according to the manufacturer's instructions for use. In particular the washer, at the end of the daily workload, has to be extensively cleaned out of salts with deionized water. Before use, the washer has to be extensively primed with the diluted Washing Solution.

The instrument weekly has to be submitted to decontamination according to its manual (NaOH 0.1 M decontamination suggested).

5 washing cycles (aspiration + dispensation of 350ul/well of washing solution + 20 sec soaking = 1 cycle) are sufficient to ensure the assay with the declared performances. If soaking is not possible add one more cycle of washing.

An incorrect washing cycle or salt-blocked needles are the major cause of false positive reactions.

- 4. Incubation times have a tolerance of  $\pm 5\%$ .
- 5. The ELISA microplate reader has to be equipped with a reading filter of 450nm and with a second filter (620-630nm, mandatory for blanking purposes). Its standard performances should be (a) bandwidth  $\leq$  10 nm; (b) absorbance range from 0 to  $\geq$  2.0; (c) linearity to  $\geq$  2.0;(d) repeatability  $\geq$  1%. Blanking is carried out on the well identified in the section "Assay Procedure". The optical system of the reader has to be calibrated regularly to ensure that the correct optical density is measured. It should be regularly maintained according to the manufacturer 's instructions.

- 6. When using an ELISA automated work station, all critical steps (dispensation, incubation, washing, reading, data handling) have to be carefully set, calibrated, controlled and regularly serviced in order to match the values reported in the sections "Validation of Test" and "Assay Performances". The assay protocol has to be installed in the operating system of the unit and validated as for the washer and the reader. In addition, the liquid handling part of the station (dispensation and washing) has to be validated and correctly set. Particular attention must be paid to avoid carry over by the needles used for dispensing and for washing. This must be studied and controlled to minimize the possibility of contamination of adjacent wells. The use of ELISA automated workstations is recommended for blood screening when the number of samples to be tested exceed 20-30 units per run.
- 7. When using automatic devices, in case the vial holder of the instrument does not fit with the vials supplied in the kit, transfer the solution into appropriate containers and label them with the same label peeled out from the original vial. This operation is important in order to avoid mismatching contents of vials, when transferring them. When the test is over, return the secondary labeled containers to 2..8°C, firmly capped.
- 8. Dia.Pro's customer service offers support to the user in the setting and checking of instruments used in combination with the kit, in order to assure compliance with the requirements described. Support is also provided for the installation of new instruments to be used with the kit.

#### L. PRE ASSAY CONTROLS AND OPERATIONS

- 1. Check the expiration date of the kit printed on the external label of the kit box. Do not use if expired.
- 2. Check that the liquid components are not contaminated by naked-eye visible particles or aggregates. Check that the Chromogen/Substrate is colorless or pale blue by aspirating a small volume of it with a sterile transparent plastic pipette. Check that no breakage occurred in transportation and no spillage of liquid is present inside the box. Check that the aluminum pouch, containing the microplate, is not punctured or damaged.
- 3. Dilute all the content of the 20x concentrated Wash Solution as described above.
- 4. Dissolve the Calibrator as described above.
- 5. Allow all the other components to reach room temperature (about 1 hr) and then mix as described.
- Set the ELISA incubator at +37°C and prepare the ELISA washer by priming with the diluted washing solution, according to the manufacturer's instructions. Set the right number of washing cycles as as reported in the specific section.
- 7. Check that the ELISA reader has been turned on at least 20 minutes before reading.
- 8. If using an automated workstation, turn it on, check settings and be sure to use the right assay protocol.
- 9. Check that the micropipettes are set to the required volume.
- 10. Check that all the other equipment is available and ready to use.
- 11. In case of problems, do not proceed further with the test and advise the supervisor.

#### M. ASSAY PROCEDURE

The assay has to be carried out according to what reported below, taking care to maintain the same incubation time for all the samples in testing.

#### Automated assay:

In case the test is carried out automatically with an ELISA system, we suggest to dispense the sample directly into the appropriate sample well of the microplate. Before the next

sample is aspirated, needles have to be duly washed to avoid any cross-contamination among samples.

Do not dilute controls/calibrator as they are ready to use.

Dispense 100 µl controls/calibrator in the appropriate control/calibration wells.

Important Note: Visually monitor that samples have been dispensed into appropriate wells.

For the next operations follow the operative instructions reported below for the Manual Assay.

It is strongly recommended to check that the time lap between the dispensation of the first and the last sample will be calculated by the instrument and taken into consideration by delaying the first washing operation accordingly.

In case an automatic workstation is used, first assure that the instrument is validated according to point I.6.

#### Manual Assay:

1. Place the required number of microwells in the microwell holder.

Store the other strips into the bag in presence of the desiccant at 2..8°C, sealed.

- Leave A1 well empty for the operation of blanking.(see also Important Note n°5)
- 2. Dispense 100 µl of Negative Control in triplicate, 100ul of Calibrator in duplicate and 100ul of Positive Control in single in proper wells, followed by 100ul of each of samples. Do not dilute Controls and Calibrator as they are pre-diluted, readv to use!

Check for the presence of samples in wells by naked eye (there is a marked color difference between empty and full wells) or by reading at 450/620nm. (samples show OD values higher than 0.100).

#### Important note:

- Strips have to be sealed with the adhesive sealing foil only when the test is performed manually. Do not cover strips when using ELISA automatic instruments.
- 3. Incubate the microplate for 45 min at 37°.
- 4. Wash the microplate with an automatic washer as reported in section I.3.
- 5. Pipette 100 µl Enzyme Conjugate into each well, except the 1st blanking well, and cover with the sealer. Check that this red coloured component has been dispensed in all the wells, except A1.

#### Important notes:

Be careful not to touch the inner surface of the well with thepipette tip when the conjugate is dispensed. Contamination might occur.

- 6. Incubate the microplate for 45 min at +37°C.
- 7. Wash the microplate with an automatic washer as in step 4.
- 8. Pipette 100 µl TMB/H<sub>2</sub>O<sub>2</sub> mixture into each well, the blank well included. Check that this pale blue coloured reagent has been dispensed in al wells. Then incubate the microplate at room temperature (18-24°C) for 15 minutes.

Important note: Do not expose to strong direct light as a high background might be generated.

9. Pipette 100 µl Sulphuric Acid into all the wells using the same pipetting sequence as in step 8 to stop the enzymatic reaction.

Addition of acid will turn the positive control and positive

samples from blue to yellow/brown.

10. Measure the color intensity of the solution in each well, as described in section I.5, with a microplate reader at 450nm (reading) and at 620-630nm (background subtraction, strongly recommended), blanking the instrument on A1 well. The Blanking Operation has to be done for the standard method only, not for the Special Assay method.

#### Important notes:

- 1. If the second filter is not available ensure that no finger prints are present on the bottom of the microwell before reading at 450nm. Finger prints could generate false positive results on reading.
- 2. Reading has to be carried out just after the addition of the Stop Solution and anyway not any longer than 20 minutes after its addition. Some self oxidation of the chromogen can occur leading to high background.
- Shaking at 350  $\pm$ 150 rpm during incubation has been З. proved to increase the sensitivity of the assay of about 20%.
- The Calibrator (CAL) does not affect the Cut-Off calculation and therefore the test results calculation. The Calibrator may be used only when a laboratory internal quality control is required by the management.
- A Special Assay Procedure that does not require blanking 5 operation may be applied in special environments or following special requests coming from clinical laboratories, both in the manual and in the automated assay protocols. In this procedure the well A1 is included in the dispensation scheme, without applying any Blanking operation of the colorimetric reading.

This method does not affect the acceptability values established in the Internal Quality Control requirements (chapter O), the formula for the calculation of the cut-off (chapter P) and the performance of the device.

#### N. ASSAY SCHEME

Method	Operations
Controls & Calibrator	100 μl
Samples	100 µl
1 <sup>st</sup> incubation	45 min
Temperature	+37°C
Wash step	n° 5 cycles with 20" of soaking OR
	n° 6 cycles without soaking
Enzyme conjugate	100 μl
2 <sup>nd</sup> incubation	45 min
Temperature	+37°C
Wash step	n° 5 cycles with 20" of soaking OR
	n° 6 cycles without soaking
TMB/H <sub>2</sub> O <sub>2</sub>	100 μl
3 <sup>rd</sup> incubation	15 min
Temperature	r.t.
Sulphuric Acid	100 μl
Reading OD	450nm / 620-630nm

An example of dispensation scheme (Standard Method) is reported below: Microplete

	Microplate											
	1	2	3	4	5	6	7	8	9	10	11	12
Α	BLK	S2										
В	NC	S3										
С	NC	S4										
D	NC	S5										
Е	CAL	S6										
F	CAL	S7										
G	PC	S8										
Н	S1	S9										
	enda:									ontro		
	CAL - Calibrator BC - Positivo Control S - Sample											

CAL = Calibrator PC = Positive Control S = Sample

An example of dispensation scheme (Special Assay Method, without Blanking Operation) is reported below:

	1	2	3	4	5	6	7	8	9	10	11	12
Α	NC	S3										
В	NC	S4										
С	NC	S5										
D	CAL	S6										
Е	CAL	S7										
F	PC	S8										
G	S1	S9										
Н	S2	S10										

#### **O. INTERNAL QUALITY CONTROL**

A check is carried out on the controls and the calibrator any time the kit is used in order to verify whether their OD450nm620-630nm values are as expected and reported in the table below.

Check	Requirements
Blank well (for standard Method)	< 0.100 OD450nm value
Negative Control (NC)	< 0.150 mean OD450nm
Calibrator (CAL)	S/Co <u>&gt;</u> 1.5
Positive Control (PC)	> 1.000 OD450nm value

If the results of the test match the requirements stated above, proceed to the next section.

If they do not, do not proceed any further and operate as follows:

Problem	Check
Blank well	1. that the Chromogen/Substrate solution
> 0.100	has not got contaminated during the
OD450nm	assay.
Negative Control (NC) > 0.150 OD450nm after	<ol> <li>that the washing procedure and the washer settings are as validated in the pre qualification study;</li> <li>that the proper washing solution has</li> </ol>
blanking	<ul> <li>been used and the washer has been primed with it before use;</li> <li>that no mistake has been done in the assay procedure (dispensation of positive control instead of negative control);</li> <li>that no contamination of the negative control or of their wells has occurred due to positive samples, to spills or to the enzyme conjugate;</li> </ul>
	<ol> <li>that micropipettes haven't got contaminated with positive samples or with the enzyme conjugate;</li> <li>that the washer needles are not blocked or partially obstructed.</li> </ol>

Calibrator	1. that the procedure has been correctly			
	executed;			
S/Co < 1.5	<ol> <li>that no mistake has been done in its distribution (ex.: dispensation of negative control instead of calibrator);</li> <li>that the washing procedure and the washer settings are as validated in the pre qualification study;</li> <li>that no external contamination of the calibrator has occurred.</li> </ol>			
Positive Control	1. that the procedure has been correctly			
< 1.000	executed;			
OD450nm	<ol> <li>that no mistake has been done in the distribution of controls (dispensation of negative control instead of positive control. In this case, the negative control will have an OD450nm value &gt; 0.150, too;</li> <li>that the washing procedure and the washer settings are as validated in the pre qualification study;</li> <li>that no external contamination of the positive control has occurred.</li> </ol>			

Should these problems happen, after checking, report any residual problem to the supervisor for further actions.

#### Important note:

The analysis must be done proceeding as the reading step described in the section M, point 10.

#### P. CALCULATION OF THE CUT-OFF

The tests results are calculated by means of a Cut-Off value determined with the following formula on the mean OD450nm/ 620-630nm value of the Negative Control (NC):

### NC + 0.200 = Cut-Off (Co)

The value found for the test is used for the interpretation of results as described in the next paragraph.

**Important note:** When the calculation of results is done by the operative system of an ELISA automated work station be sure that the proper formulation is used to calculate the Cut-Off value and generate the right interpretations of results.

#### **Q. INTERPRETATION OF RESULTS**

Test results are interpreted as ratio of the sample OD450nm/620-630nm and the Cut-Off value (or S/Co) according to the following table:

S/Co	Interpretation
< 0.9	Negative
0.9 - 1.1	Equivocal
> 1.1	Positive

A **negative** result indicates that the patient has not been infected by HTLV I&II or that the blood unit may be transfused.

Any patient showing an **equivocal** result should be tested again on a second sample taken 1-2 weeks later from the patient and examined. The blood unit should not be transfused.

Doc.:	INS HTLVABULTRA.CE/eng	Page	7 of 8	Rev.: 4	Date: 2021/05	
-------	------------------------	------	--------	---------	---------------	--

A **positive** result is indicative of HTLV I&II infection and therefore the patient should be treated accordingly or the blood unit should be discarded.

#### Important notes:

- Interpretation of results should be done under the supervision of the responsible of the laboratory to reduce the risk of judgment errors and misinterpretations.
- Any positive result should be confirmed by an alternative method capable to detect anti HTLV antibodies (RIBA or similar), and possibly with a Molecular Biology assay, before a diagnosis of HTLV infection is formulated.
- 3. When test results are transmitted from the laboratory to an informatics centre, attention has to be done to avoid erroneous data transfer.
- 4. Diagnosis of HTLV I&II infection has to be done and released to the patient only by a qualified medical doctor.

An example of calculation is reported below:

The following data must not be used instead or real figures obtained by the user.

 Negative Control:
 0.079 – 0.080 – 0.081 OD450nm

 Mean Value:
 0.080 OD450nm

 Lower than 0.150 – Accepted

 Positive Control:
 2.589-2591 OD450nm

 Mean Value:
 2.590 OD450nm

 Higher than 1.000 – Accepted
 Cut-Off = 0.080+0.200 = 0.280

 Calibrator:
 1.030 - 1.036 OD450nm

 Mean value:
 1.033 OD450nm
 S/Co = 3.7

 S/Co higher than 1.5 - Accepted
 S/Co = 3.7

 Sample 1:
 0.070 OD450nm

 Sample 2:
 1.690 OD450nm

 Sample 1 S/Co < 0.9 = negative</td>
 sample 2 S/Co > 1.1 = positive

#### **R. PERFORMANCES**

Evaluation of Performances has been conducted in accordance to what reported in the Common Technical Specifications or CTS:2009.

#### 1. ANALYTICAL SENSITIVITY

The limit of detection of the assay has been calculated by means of the preparation Accurun 24, lot # 118956, produced by Seracare Life Sciences, USA.

The table below reports the results obtained for this material with three lots of products (P1, P2 and P3)

Accurun 24 was diluted in HTLV Ab negative serum and examined in 4 replicates.

#### **ACCURUN 24**

Dilution	P1	P2	P3
	OD450nm	OD450nm	OD450nm
4x	2.981	2.957	3.455
8x	1.964	1.856	1.992
16x	0.935	0.820	0.971
32x	0.551	0.453	0.562
64x	0.318	0.357	0.434
128x	0.201	0.195	0.251
diluent	0.040	0.059	0.055

The product shows an analytical sensitivity better than the reference kit of previous generation.

#### 2. DIAGNOSTIC SPECIFICITY AND SENSITIVITY

The Performance Evaluation of the device was carried out in an trial conducted on more than total 5000 samples, according to the requirements of the CTS:2009.

Internally some other tests were carried out on commercially available panels of characterized positive samples.

#### 2.1 Diagnostic Specificity:

It is defined as the probability of the assay of scoring negative in the absence of specific analyte. In addition to the first study, where a total of more 5000 samples, including unselected donors, hospitalized patients and potentially cross reacting specimens, were examined, matching the requirements of CTS:2009, the diagnostic specificity was recently assessed by testing a total of 3354 negative samples on five different lots. A value of specificity of 100% was observed.

Both plasma, derived with different standard techniques of preparation (citrate, EDTA and heparin), and sera were tested as well to assure no interference due to the sample preparation. Frozen specimens have been tested, as well, to check for interferences due to collection and storage.

No false reactivity due to the method of specimen preparation has been observed.

#### 2.2 Diagnostic Sensitivity

It is defined as the probability of the assay of scoring positive in the presence of specific analyte.

The diagnostic sensitivity was assessed in the internal Performance Evaluation on a total number of more than 470 specimens coming from both HTLV I (n=348) and HTLV II (n=125) infection.

The diagnostic sensitivity was additionally evaluated on

- The panel code PRP 207/M supplied by BBI, USA;
- Two panels of European origin produced by EFS, France, and based on samples of European origin;
- NIBSC UK Monitor Sample for anti-HTLV-I, Lot 03/104-009;

against the kit produced by Murex (values shown as reported in the leaflet of the panel or tested internally using Murex kit); Samples were evaluated in duplicate (n = 2). A diagnostic sensitivity of 100% was found.

Results obtained on panels are reported as follows:

#### BBI Panel code PRP 207/M

Sample N°	Result	KIT S/Co	Murex S/Co
1	+	15.1	11.8
2	+	8.0	11.6
3	+	13.3	11.6
4	+	17.4	11.8
5	+	17.4	11.6
6	/	/	/
7	+	17.4	11.6
8	+	17.4	11.6
9	+	17.4	11.6
10	+	17.0	11.6
11	+	10.4	11.8
12	+	17.4	11.6
13	+	17.4	11.6
14	+	17.4	11.6
15	-	0.5	0.2

Doc.:	INS HTLVABULTRA.CE/eng	Page	8 of 8	Rev.: 4	Date: 2021/05
-------	------------------------	------	--------	---------	---------------

#### EFS - Panel Ac HTLV lot # 07.140625

Member	Kit	Murex
N°	S/Co	S/Co
1	1.5	4.2
2	7.6	6.9
3	4.7	8.6
4	4.0	8.1
5	2.5	4.5
6 (diluent)	0.2	0.2

#### EFS - Panel Ac HTLV lot # 05/08.2012.22C

Member	Kit	Murex	typing
N°	S/Co	S/Co	
1	3.4	10.1	p19l/p24/gp46l
2	12.2	13.3	p19l/gp46l/gp21
3	10.6	9.4	gp46l
4	11.1	9.6	gp46II

#### NIBSC - Lot 03/104-009

P1	P2	P3	Murex
S/Co	S/Co	S/Co	S/Co
1.8	1.3	1.9	2.1

#### 3. PRECISION:

The Negative Control (NC), the Calibrator (CAL) and the Positive Control (PC) of the device were examined in 16 replicates for three times (total n = 48) on three different lots of the product.

The coefficients of variation (% CV) for the between and for the within assays were calculated.

From the OD450nm values obtained the following mean values have been derived:

	NC	CAL	PC
OD450nm	0.095	1.135	2.495
DEV.ST.	0.010	0.070	0.074
%CV	9.6	6.2	3.0

The variability shown in the table does not lead to any misinterpretation in particular of a sample closed to the diagnostic threshold of the assay.

#### Important note:

The performance data have been obtained proceeding as the reading step described in the section *M*, point 10.

#### S. LIMITATIONS

Repeatable false positive results, not confirmed by Western Blot or similar confirmation techniques, were assessed as less than 0.1% of the normal population.

Frozen samples containing fibrin particles or aggregates after thawing have been observed to generate some false results.

#### REFERENCES

1.Biomed Biotechnol. 2008; 2008: 846371.

Published online 2008 June 11. doi: 10.1155/2008/846371.

2.Lee H, Burczak JD and Shih, Manual of Clinical Microbiologogy, 6<sup>th</sup> ed, Murray PR, Baron EJ, Pfaller MA, et al, eds, Washington, DC: American Society for Microbiology, 1995, 1115-20, Progressive Multifocal.

3.Stoeckle W, Introduction – Type C Oncoviruses including Human T-Cell Lymphotropic Viruses Types I and II, Pricipals an Practice of Infectious Diseases, 4<sup>th</sup> ed, Mandell GL, Bennett JE, and Dolin R, eds, New York, NY,: Churcill Livingstone, 1955, 1579-84

4.Human T lymphotropic virus types I and II proviral sequences in Argentinian blood donors with indeterminate Western blot patterns.<u>Mangano AM</u>, <u>Remesar M</u>, <u>del Pozo A</u>, <u>Sen L</u>.

All the IVD Products manufactured by the company are under the control of a certified Quality Management System approved by an EC Notified Body. Each lot is submitted to a quality control and released into the market only if conforming with the EC technical specifications and acceptance criteria.

Manufacturer: Dia.Pro Diagnostic Bioprobes S.r.l. Via G. Carducci n° 27 – Sesto San Giovanni (MI) – Italy

**CE** 0318